243 related articles for article (PubMed ID: 27943008)
1. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
2. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
3. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
4. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Hertz DL; Speth KA; Kidwell KM; Gersch CL; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Breast Cancer Res Treat; 2017 Oct; 165(3):659-668. PubMed ID: 28643023
[TBL] [Abstract][Full Text] [Related]
5. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurement.
Faltinová M; Vehmanen L; Lyytinen H; Haanpää M; Hämäläinen E; Tiitinen A; Blomqvist C; Mattson J
Breast Cancer Res Treat; 2023 Oct; 201(3):425-435. PubMed ID: 37491651
[TBL] [Abstract][Full Text] [Related]
6. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
[TBL] [Abstract][Full Text] [Related]
7. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
8. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
9. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
Breast Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38649619
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
11. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
12. Effects of
Dempsey JM; Kidwell KM; Gersch CL; Pesch AM; Desta Z; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM; Hertz DL
Pharmacogenomics; 2019 Jun; 20(8):571-580. PubMed ID: 31190621
[No Abstract] [Full Text] [Related]
13. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Bertelsen BE; Viste K; Helland T; Hagland M; Søiland H; Geisler J; Lende TH; Lønning PE; Sagen JV; Mellgren G; Almås B
J Clin Endocrinol Metab; 2022 Apr; 107(5):1368-1374. PubMed ID: 34958096
[TBL] [Abstract][Full Text] [Related]
15. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Bell LN; Nguyen AT; Li L; Desta Z; Henry NL; Hayes DF; Wolff AC; Stearns V; Storniolo AM; Flockhart DA;
J Clin Pharmacol; 2012 Dec; 52(12):1852-60. PubMed ID: 22174434
[TBL] [Abstract][Full Text] [Related]
16. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
18. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Geisler J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):245-53. PubMed ID: 14623518
[TBL] [Abstract][Full Text] [Related]
20. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
